You are here
Articles on Gastrointestinal Cancer
A selection of peer-reviewed articles on Gastrointestinal Cancer. All content available on the Advances in Gastrointestinal Cancer Resource Center, including original and review articles, interviews, guidelines and congress highlights, is independently selected by the members of the Editorial Board.
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer
Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, et al.
Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging
Tatsubayashi T, Tanizawa Y, Miki Y, Tokunaga M, Bando E, Kawamura T, et al.
High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability
Polom K, Marrelli D, Pascale V, Roviello G, Voglino C, Rho H, et al.
Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, et al.
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al.
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, et al
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, et al
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, et al.